Latest News - CSL Seqirus
Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core.
www.cslseqirus.usHere are the latest influenza vaccine news highlights you might find relevant.
-
WHO and global health agencies emphasize vaccination as the best defense early in the season, with ongoing guidance on strain selection and surveillance to inform vaccine composition. This remains a priority as new variants emerge, reinforcing the need for high vaccination coverage.[3]
-
U.S. federal efforts continue to invest in next-generation vaccines, including mRNA platforms and cell-based approaches, to accelerate development and improve effectiveness against circulating strains; recent funding announcements aim to speed up testing and deployment options for flu vaccines.[2]
-
Regulatory and public health bodies periodically update the recommended strains for upcoming seasons, including how egg- and cell-based vaccines are chosen, with official communications noting this should not disrupt vaccine availability for the public.[4]
-
Industry updates show manufacturers advancing new quadrivalent and cell-based vaccines, with some public announcements highlighting real-world effectiveness data and implications for future vaccine design and stockpiling.[1]
-
Country-level developments include new influenza vaccines entering the market (e.g., quadrivalent vaccines addressing additional strains) and efforts to align national procurement with WHO strain recommendations to improve population protection.[5]
If you’d like, I can narrow this to a specific region (e.g., United States, Europe, or a city near Santa Monica) or pull the most recent regulatory guidance and vaccination recommendations for the 2025–2026 season. I can also summarize key takeaways for clinicians, policymakers, or the general public.
Would you like a concise country/regional briefing, a clinical guidance summary, or a consumer-oriented overview?
Citations:
- WHO and health agencies on vaccination as best defense and surveillance guidance.[3]
- U.S. funding for mRNA bird flu vaccines and accelerated testing programs.[2]
- FDA/WHO strain selection and vaccine availability notes.[4]
- Industry updates on quadrivalent/cell-based vaccines and real-world effectiveness data.[1]
- Global and national vaccine updates and new vaccine introductions.[5]